Clinical Trial Detail

NCT ID NCT01853644
Title Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements no
Sponsors Northwestern University
Indications

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer

Therapies

Tivozanib

Age Groups: adult

No variant requirements are available.